Oral Psoriasis Drug From Takeda Demonstrates Strong Skin Clearance in Trials
Takeda shares positive Phase 3 data for its oral psoriasis drug zasocitinib, showing high skin clearance ahead of its planned FDA filing.
Why It Matters
Takeda's new psoriasis medicine worked really well in tests, which means it might help lots of patients. When a company's medicine does well in tests, that usually makes people more interested in the company.
This read is generated by AI from raw market data and is for education only. It is not financial advice, not a signal, and not a recommendation to buy or sell.
Tickers in Play
Source: Benzinga · Read the original report at the publisher. Headline and figures shown for context; data may be delayed.
Disclosure: Educational and informational purposes only — not financial advice. We educate, not advise. Market data may be delayed up to 15 minutes unless marked real-time. Past performance is not indicative of future results.